Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

被引：0
|
作者：
Jeffrey P Nadler
Joseph C Gathe
Richard B Pollard
Gary J Richmond
Qiming Liao
Sandy Griffith
C Tracey Lancaster
Jaime E Hernandez
Keith A Pappa
机构：
[1] University of South Florida,College of Medicine
[2] Park Plaza Hospital,GlaxoSmithKline
[3] University of Texas Medical Branch,undefined
[4] Broward General Medical Center,undefined
[5] Research Triangle Park,undefined
来源：
BMC Infectious Diseases | / 3卷
关键词：
Amprenavir; ritonavir; HIV-1 infection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
    Nadler, JP
    Gathe, JC
    Pollard, RB
    Richmond, GJ
    Liao, QM
    Griffith, S
    Lancaster, CT
    Hernandez, JE
    Pappa, KA
    BMC INFECTIOUS DISEASES, 2003, 3 (1)
  • [2] Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir 400 mg indinavir in HIV-infected patients
    Ghosn, J
    Lamotte, C
    Ait-Mohand, H
    Wirden, M
    Agher, R
    Schneider, L
    Bricaire, F
    Duvivier, C
    Calvez, V
    Peytavin, G
    Katlama, C
    AIDS, 2003, 17 (02) : 209 - 214
  • [3] Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Boyd, MA
    Aarnoutse, RE
    Ruxrungtham, K
    Stek, M
    van Heeswijk, RPG
    Lange, JMA
    Cooper, DA
    Phanuphak, P
    Burger, DM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (02) : 134 - 139
  • [4] Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: Comparison of 800/100 mg and 400/100 mg twice daily
    Konopnicki, D
    De Wit, S
    Crommentuyn, K
    Huitema, A
    Clumeck, N
    HIV MEDICINE, 2005, 6 (01) : 1 - 6
  • [5] Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily
    Autar, RS
    Ananworanich, J
    Apateerapong, W
    Sankote, J
    Hill, A
    Hirschel, B
    Cooper, D
    Lange, J
    Phanuphak, P
    Ruxrungtham, K
    Burger, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) : 785 - 790
  • [6] Study PROF 1004: Steady-state pharmacokinetics of amprenavir 600 mg bid and ritonavir 100 mg bid with or without NNRTI in HIV-1 infected patients
    Goujard, G
    Meynard, JL
    Choudet, N
    Bollens, D
    Rousseau, C
    Demarles, D
    Vincent, I
    Taburet, AM
    AIDS, 2000, 14 : S93 - S93
  • [7] Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1-Infected Patients
    Martinez-Rebollar, Maria
    Munoz, Ana
    Perez, Inaki
    Hidalgo, Susana
    Brunet, Merce
    Laguno, Montserrat
    Gonzalez, Ana
    Calvo, Marta
    Lonca, Montserrat
    Blanco, Jose Luis
    Martinez, Esteban
    Maria Gatell, Jose
    Mallolas, Josep
    THERAPEUTIC DRUG MONITORING, 2013, 35 (04) : 552 - 556
  • [8] Assessment of Amprenavir plasma Cmin levels in patients receiving once-daily fos-amprenavir in combination with either 100 or 200 mg ritonavir
    Muret, P.
    Muret, P.
    Montange, D.
    Bettinger, D.
    Faller, J. P.
    Beck-Wirth, G.
    Martha, B.
    Hoen, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 44 - 44
  • [9] Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients
    Boyd, M
    Mootsikapun, P
    Burger, D
    Chuenyam, T
    Ubolyam, S
    Mahanontharit, A
    Sangkote, J
    Bunyaprawit, P
    Horsakulchai, M
    Lange, J
    Cooper, D
    Phanuphak, P
    Ruxrungtham, K
    ANTIVIRAL THERAPY, 2005, 10 (02) : 301 - 307
  • [10] High rate of gastrointestinal side effects in patients treated with amprenavir, lopinavir and ritonavir (200 mg twice daily)
    Mauss, S
    Scholten, S
    Wolf, E
    Berger, F
    Schmutz, G
    Postel, E
    Rockstroh, JK
    ANTIVIRAL THERAPY, 2002, 7 (03) : L61 - L61
12345